Psychotic symptoms in severe MTHFR deficiency and their successful treatment with betaine.
Bönig
Halvard
H
Division of Paediatric Metabolic Disease, Heinrich-Heine University Medical Centre, Moorenstrasse 5, 40225, Düsseldorf, Germany.
Däublin
Gerhard
G
Division of Paediatric Metabolic Disease, Heinrich-Heine University Medical Centre, Moorenstrasse 5, 40225, Düsseldorf, Germany.
Schwahn
Bernd
B
Division of Paediatric Metabolic Disease, Heinrich-Heine University Medical Centre, Moorenstrasse 5, 40225, Düsseldorf, Germany.
Wendel
Udo
U
Division of Paediatric Metabolic Disease, Heinrich-Heine University Medical Centre, Moorenstrasse 5, 40225, Düsseldorf, Germany. wendelu@uni-duesseldorf.de.
D001622:Betaine / Q000494:pharmacology / Q000627:therapeutic use*; D020739:Brain Diseases, Metabolic, Inborn / Q000188:drug therapy*; D002648:Child; D004305:Dose-Response Relationship, Drug; D006212:Hallucinations / Q000188:drug therapy*; D006801:Humans; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000172:deficiency*
D001622:Betaine; D000587:Oxidoreductases Acting on CH-NH Group Donors; D042965:Methylenetetrahydrofolate Reductase (NADPH2)